Could This Be the First Parkinson's Disease Modifier?

Episode notes

Send us Fan Mail Is the era of just managing Parkinson's symptoms finally coming to an end? In this clip from our episode “How AI Is Helping The Fight Against Parkinson’s”, host David E. Williams and guest Gene Mack, CEO of Gain Therapeutics, share why the early signals from their lead drug candidate are too compelling to ignore. Listen to the full episode here ️️ABOUT GENE MACK Gene Mack serves as Chief Executive Officer and President of Gain Therapeutics. He joined the Company in April 2024 and brings 25 years of experience in the life sciences sector spanning clinical research, financing and capital markets, investing, corporate strategy and business development. Prior to joining Gain, Gene was CFO at privately held Imcyse SA between 2021 and 2023. Previous to Imcyse, Gene was CFO at OncoC4, a privately held biotechnology company that spun out of Merck & Co’s (MSD) $475 million acquisition of OncoImmune in 2020 where he had also been CFO. Before that, he has held the CFO role for several development- and commercial-stage biopharmaceutical companies, raising over $350 million in IPO and other equity transactions.

• GLP-1s May Reduce Cancer Progression36 / 100
• The Business & Science Behind the GLP-1 Boom64 / 100
• Why We Can Never Have Enough Doctors60 / 100
• The Future of Medicine Is Already Here w/ Bertalan Mesko, The Medical Futurist Institute
• Why Insulin Never Reaches the Liver